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Novelty and impact statements 
A retrospective assessment of the value of high-dose chemotherapy and 
autologous stem cell rescue (HDC+AuSCR) and re-irradiation in patients 
with relapsed intracranial germ cell tumors (GCTs). Those with germinoma 
had reasonable outcomes with either standard-dose chemotherapy with re-irradiation  
or HDC+AuSCR; those with relapsed non-germinomatous GCTs (NGGCTs) were 
only salvaged with HDC+AuSCR, but then only rarely. Counselling regarding poor 
outcomes for relapsed NGGCT patients is required prior to embarking on treatment. 
 
Word count: 4,021; Figures/Tables: Four Figures, Two Tables 
Running title: Relapsed intracranial germ cell tumors 
Keywords: germ cell tumor; high-dose chemotherapy; intracranial; non-germinoma; 
relapse, re-irradiation. 
Presented in part at: 15
th
 International Symposium on Pediatric Neuro-oncology, 
Toronto, Canada, June 24-27, 2012 and 3
rd
 International CNS Germ Cell Tumor 
Symposium, Cambridge, UK, April 17-20, 2013.  
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Abstract 
We aimed to retrospectively assess treatments/outcomes, including the value of high-
dose-chemotherapy and autologous-stem-cell-rescue (HDC+AuSCR) and re-
irradiation, in a large, European patient-cohort with relapsed intracranial germ-cell-
tumors (GCTs) receiving uniform first-line therapy, including radiotherapy as 
standard-of-care. Fifty-eight UK/German patients (48 male/10 female) with relapsed 
intracranial-GCTs [13 germinoma/45 non-germinomatous GCT(NGGCT)] treated 
1996-2010 as per the SIOP-CNS-GCT-96 protocol were evaluated. For germinoma, 
six patients relapsed with germinoma and five with NGGCT (one palliative, one 
teratoma patient excluded). Five-year overall-survival (OS) for the whole-group 
(n=11) was 55%. Four of six germinoma relapses and two of five relapsing with 
NGGCT were salvaged; patients were salvaged with either standard-dose-
chemotherapy (SDC) and re-irradiation or HDC+AuSCR with/without re-irradiation. 
Of 45 relapsed NGGCT patients, 13 were excluded (3 non-protocol adherence, 5 
teratoma, 5 palliation). Five-year OS for the remaining 32 relapsed malignant 
NGGCT patients treated with curative intent was 9%(95%CI: 2-26%). By treatment 
received, 5-year OS for the 10 patients receiving SDC and 22 patients treated with 
intention for HDC+AuSCR was 0%(0-0%) and 14%(3-36%), respectively. The three 
relapsed NGGCT survivors had raised HCG markers alone; two received additional 
irradiation. Patients with relapsed germinoma had better 5-year OS than those with 
relapsed NGGCT (55%vs.9%; p=0.007). Patients with relapsed germinoma were 
salvaged both with SDC and re-irradiation or HDC+AuSCR with/without re-
irradiation; which both represent valid treatment options. Outcomes for malignant 
relapse following initial diagnosis of NGGCT were exceptionally poor; the few 
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survivors received thiotepa-based HDC+AuSCR, which is a treatment option at first 
malignant relapse for such patients, with further surgery/irradiation where feasible.  
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Introduction  
 
Malignant intracranial germ cell tumors (GCTs) are a rare group of predominantly 
midline neoplasms
1
, often classified into germinoma or non-germinomatous tumors 
(NGGCTs). The latter group is particularly heterogeneous and includes the malignant 
subtypes yolk sac tumor (YST) and choriocarcinoma (CHC) [which secrete the tumor 
markers alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG), 
respectively], as well as embryonal carcinoma (EC)
2
. Most NGGCTs are mixed 
malignant GCTs, containing more than one subtype, which makes diagnostic work-
up, classification and management more complex
3,4
. 
 
Germinomas comprise ~60% of all intracranial GCTs
5
, and are extremely sensitive to 
multimodal therapy
6
, including both chemotherapy and radiotherapy. Recent 
strategies have focused on maintaining excellent event-free (EFS) and overall (OS) 
survival rates, whilst reducing toxicity and late-effects
5,7–9
. The European non-
randomized trial, SIOP-CNS-GCT-96, compared craniospinal radiotherapy (CSI) 
alone (24 Gy plus 16 Gy tumor-boost), Option-A, with  two courses of combination 
‘carboPEI’ chemotherapy (carboplatin/etoposide,/ifosfamide) and focal radiotherapy 
(40 Gy), Option-B, for localized intracranial germinomas
5
. Metastatic disease was 
treated with either CSI alone or combination chemotherapy (as for localized disease) 
and CSI. Outcomes were excellent, with five-year EFS of 94% and 88% for localized 
patients treated with Options-A and -B, respectively
5
. An excess of ventricular 
relapses for Option-B patients was addressed by the addition of whole ventricular 
irradiation for the current SIOP-CNS-GCT-II study
5
. In germinoma patients with 
metastatic disease, five-year EFS and OS was 98%
5
.  
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Patients with NGGCT on the SIOP-CNS-GCT-96 study received four courses of PEI 
chemotherapy (cisplatin/etoposide/ifosfamide), followed by 54 Gy focal radiotherapy 
for localized disease and 30 Gy CSI with 24 Gy tumor-boost for metastatic disease. 
The rationale for treatment was based on studies that used a single chemotherapy 
protocol to treat both extracranial and intracranial GCT, with the addition of radiation 
for intracranial cases
4,10
. Progression-free survival (PFS) was inferior to that observed 
for germinoma, at 69% and 67% for localized and metastatic disease, respectively
11
. 
Recently, good outcomes for intracranial NGGCT patients were reported in a 
Children’s Oncology Group study
12
. 
 
As a consequence of the rarity of intracranial GCTs and the general success of their 
treatment, relapses are rare. As a result, there is little available evidence to guide 
optimal management
13
. A widely reported study of relapsed intracranial GCT 
evaluated the efficacy of HDC+AuSCR in a small, highly heterogeneous group of 
patients who had received variable first-line treatments
14
. Eight of the 21 patients 
reported had not received prior radiotherapy, which would now be considered 
standard-of-care
2
. Furthermore, there was unavoidable selection bias in the patients 
described, as those who experienced rapid tumor progression or did not have a good 
response to re-induction chemotherapy did not proceed to HDC+AuSCR and were 
therefore not reported
14
. As a result, the encouraging outcomes reported (78% and 
33% survival for germinoma and NGGCT, respectively)
14
 are likely to be an 
overestimate of the true salvage rates for patients who relapse following optimal first-
line treatment. A more recent small study of HDC+AuSCR for relapsed intracranial 
GCT patients reported promising survival rates
15
, however, first-line treatments were 
variable. 
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Here, we present data from the largest cohort of patients with relapsed intracranial 
GCTs described to date, treated with first-line treatment as per the European SIOP-
CNS-GCT-96 trial protocol, which included radiotherapy as standard. The results 
described here will inform future approaches to the management of these patients, 
with the aim of optimizing survival. 
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Patients and Methods 
 
Methods. Both the UK and German groups, as major contributors to the SIOP-CNS-
GCT-96 trial, treated sufficient numbers of patients according to the protocol to have 
a suitable patient cohort experiencing relapse to describe separately. In addition, UK 
and German groups made resources available to undertake this project. Accordingly, 
follow-up data on UK and German patients treated on the SIOP-CNS-GCT-96 trial, 
stored on a central database, was augmented in the UK by additional questionnaire-
based data-collection, which captured additional non-trial patients who were treated 
according to the protocol. This anonymized service evaluation required no additional 
ethical approvals. Resources were not available to undertake additional questionnaire-
based data collection to identify non-trial patients in Germany, or other countries who 
participated in the trial. Patients included in the study received treatment between 
1996 and 2010. The SIOP-CNS-GCT-96 trial was open from 1996 and following 
closure in the UK in 2006, non-trial patients were treated on trial-based guidelines. 
Data were collected during 2011, with a further update to exclude further events in 
2014. Data requested included full clinico-pathological details at primary diagnosis 
and relapse, confirmation of first-line treatment, relapse treatments received and 
outcome. The clinical characteristics of the subset of patients described here were 
similar to the trial group as a whole.  
 
Overall patient cohort. A total of 58 relapsed central nervous system (CNS) GCT 
cases were identified from the UK (n=33) and Germany (n=25), comprising 48 male 
and 10 female patients, with an overall median age at diagnosis of 14.0 years (y) 
(range 1.4-30.0 y) and median follow-up from original diagnosis of 23 months (m) 
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(range 7-203 m). There were 13 cases with an original diagnosis of germinoma (10 
UK/three German; nine male/four female) and 45 patients who relapsed following an 
NGGCT diagnosis (23 UK/22 German; 39 male/six female). Of the 58 patients 
identified in total, 41 (71%) were treated on trial (16 UK and 25 German patients). 
The trial database only captured data up until the time of relapse, and therefore 
subsequent information regarding treatments and outcome available on the database 
was variable. Consequently, further anonymized information was sought from treating 
centers. An additional 17 (29%) UK non-trial patients were identified by 
questionnaire-based survey, hence the relative larger number of UK relapses. For 
germinoma, the 10 UK patients comprised five trial and five non-trial patients (in 
addition to the three German trial patients). For the 23 UK NGGCT cases, 11 patients 
were treated on trial with a further 12 non-trial patients identified (in addition to the 
22 German trial patients). From the trial database, overall outcomes for UK and 
German patients receiving first-line treatment were similar to overall trial results for 
patients from all participating countries (data not shown), and hence represented an 
appropriate and non-biased cohort in which to study relapse. It should be noted that 
the purpose of this work was not to assess the actual relapse rate for CNS GCTs and, 
indeed, as both trial and non-trial patients were included, it was not possible to 
provide an overall denominator defining the total number of patients treated upfront, 
which are provided elsewhere 
5,11
. See Figure 1 for a summary flow-diagram of 
patients included in the study. 
 
Relapsed germinoma patients – initial diagnostic and staging work-up. Clinico-
pathological data at diagnosis are summarized in Supplementary Table 1. The median 
age at diagnosis of the 13 patients who relapsed following a germinoma diagnosis was 
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12.3 y (range 4.8-16.3 y). Primary disease site was pineal gland (n=5), suprasellar 
region (n=4), bifocal (i.e. suprasellar and pineal regions, considered localized disease 
if no evidence of disease elsewhere; n=3) and basal ganglia (n=1). All cases 
underwent histological confirmation of germinoma diagnosis. One of 13 cases (8%) 
was metastatic at diagnosis.  
 
Relapsed germinoma patients – first-line treatment received and response. Data are 
summarized in Supplementary Table 1. Seven of 13 patients (54%) received CSI as 
per Option-A treatment on the SIOP-CNS-GCT-96 protocol, and 6/13 (46%) patients 
received Option-B treatment with combined chemotherapy and focal radiotherapy. In 
the absence of central radiological review to assess response in the SIOP-CNS-GCT-
96 trial, local radiological reports were utilized for both trial and non-trial patients in 
this study. Eight of 13 patients (62%) achieved a complete response (CR) to first-line 
therapy, 4/13 achieved a partial response (PR; 31%) and data were unavailable for 
one patient (8%).  
 
Relapsed NGGCT patients – initial diagnostic and staging work-up. Clinico-
pathological data are summarized in Supplementary Table 2. The median age at 
diagnosis of the 45 patients who relapsed following an NGGCT diagnosis was 14.4 y 
(range 1.4-30.0 y). Primary disease site was pineal (n=27), suprasellar (n=8), bifocal 
(n=4), basal ganglia (n=3) and cerebral hemisphere (n=3). Forty-one of 45 cases 
(91%) had markers above SIOP-CNS-GCT-96 defined thresholds (i.e. serum or CSF 
AFP >25 ng/ml and/or HCG >50 IU/l) and the remaining four cases had negative 
markers, so underwent a neurosurgical biopsy which histologically confirmed EC. Six 
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of 45 cases (13%) were metastatic at diagnosis, defined by imaging and/or CSF 
cytology.  
 
Relapsed NGGCT patients – first-line treatment received and response. Data are 
summarized in Supplementary Table 2. Forty-two of 45 patients (93%) received 
standard PEI chemotherapy, and three (7%) received non-protocol chemotherapy and 
were excluded from subsequent relapse outcome analysis: one received ‘high-dose’ 
PEI due to presentation after trial closure with AFP ≥1000 ng/ml, as per the SIOP-
CNS-GCT-II trial treatment prior to its opening (physician choice), and two received 
other chemotherapy (no indication given). Forty-three of 45 patients (96%) received 
radiotherapy, one had progressive disease prior to receiving radiotherapy and the 
other was considered too young (19m) at diagnosis. As per standard criteria
16
, 14 of 
45 patients (31%) achieved CR at the end of first-line treatment, 20/45 (44%) 
achieved partial remission (PR), 6/45 (13%) had stable disease (SD), 4/45 (9%) had 
progressive disease (PD) and data were unavailable for one patient (2%). Five of the 
26 patients (19%) with a PR/SD response underwent surgical resection for residual 
disease. 
 
Statistical analysis. EFS was calculated from day of relapse to date of progression or 
death, whichever was earlier, with censoring taken on the date of last clinical contact. 
OS was calculated from date of relapse to date of death. Estimated EFS/OS rates were 
calculated by Kaplan-Meier survival method. EFS/OS values were given with 95% 
confidence intervals (CI) in parentheses, and differences in outcome between groups 
assessed by log-rank test (p≤0.05 significant), where numbers were sufficient for such 
statistical analyses/comparisons. 
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Results  
 
Relapsed patients – details of relapse. Data are summarized in Figure 1, Table 1, 
Table 2 and Supplementary Results. 
 
Relapsed germinoma patients – relapse treatments and outcomes. Data are 
summarized in Figure 1 and Table 1. Two patients (both treated initially on Option-A) 
were excluded from further evaluation – one was a pure immature teratoma relapse 
and one declined active treatment. The majority of the 11 remaining patients who had 
a malignant relapse treated with curative intent following original germinoma 
diagnosis received re-induction chemotherapy with a platinum-based (carboplatin or 
cisplatin) strategy (Table 1), with variable subsequent treatments. This resulted in a 5-
year EFS and OS of 5/11 (45%) and 6/11 (55%), respectively, with median EFS and 
OS of 20 m and 53 m for the whole group, respectively (Figure 2). Median OS for the 
six survivors was 84 m (range 53-194 m). We first compared OS by original first-line 
treatment, irrespective of subsequent relapse chemotherapy delivered. Of the five 
patients treated on Option-A, two survived (40%), with four of six surviving (67%) 
who initially received Option-B (Supplementary Table 1 and Table 1). Next, we 
compared the cohort by relapse chemotherapy/re-irradiation received. Three out of 
seven patients (43%) treated with standard-dose-chemotherapy (SDC) had complete 
responses and no further relapses/events; the figure was 2/4 (50%) who received 
HDC+AuSCR at first relapse. Two patients received HDC+AuSCR following further 
relapse after SDC, of whom one was salvaged, taking the OS of patients treated with 
SDC at initial relapse to 4/7 (57%) (Table 1).  Six out of seven patients (86%) treated 
with SDC received additional radiotherapy (four focal, plus two patients who had CSI 
having received focal radiotherapy at original diagnosis). One SDC patient, who had 
Page 13 of 38
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14 
 
CSI at diagnosis, received no further radiotherapy at relapse. None of the four patients 
who were treated with intent for HDC+AuSCR received additional radiotherapy at 
relapse.  Finally, we compared the group by presence or absence of positive tumor 
markers at relapse. For marker-negative (i.e. germinoma) cases at relapse, 5-year EFS 
and OS was 3/6 (50%) and 4/6 (67%), respectively. Three of these six patients were 
treated with SDC (in addition to focal re-irradiation), of whom two (67%) were 
salvaged – one with SDC alone and the other with additional HDC+AuSCR following 
a second relapse. Three of the six patients were treated with HDC+AuSCR at first 
relapse, with no further re-irradiation, of whom two (67%) were salvaged. Of the five 
patients who relapsed and were marker-positive (i.e. classified as NGGCT at relapse), 
two patients of four (50%) were successfully treated with SDC alone (Table 1). Of 
these two survivors, one had a CNS relapse (treated with SDC and CSI) with a 
maximum HCG level of only 55 IU/l (patient G12); the other had an exclusively 
extracranial relapse due to tumor seeding through a ventriculo-peritoneal shunt, with 
only germinoma confirmed on cytology of ascitic fluid and an HCG of 397 IU/l 
(G13), described elsewhere
17
. The other germinoma patient who relapsed with 
positive HCG (patient G2; maximum HCG value 734 IU/l), received SDC, but 
subsequently died following further relapses after having received HDC+AuSCR. 
One germinoma patient relapsing as NGGCT received HDC+AuSCR at first relapse, 
who also subsequently died (Table 1). 
 
Relapsed NGGCT patients - relapse treatment and outcomes. Data are summarized in 
Figure 1 and Table 2. Of the 45 relapsed NGGCT patients, 13 were excluded, 
comprising non-protocol first-line chemotherapy (n=3), relapse with pure teratoma, 
treated with surgery alone (n=5), and a further five patients who received palliation 
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only (see Figure 1). As for relapsed germinoma, the majority of relapsed NGGCT 
patients treated with curative intent received re-induction chemotherapy with a 
platinum-based (carboplatin or cisplatin) strategy, with most of those patients then 
proceeding to high-dose therapy (Table 1). Five-year EFS and OS for these 32 
remaining malignant patients treated with curative intent was 9% (95% CI: 2-26%), 
with a median EFS and OS of 8m and 12m, respectively (Figure 2). Median OS for 
the three survivors was 105 m (range 88-127 m). Five-year OS for the 10 patients 
who received SDC was 0% (0-0%), with median survival of 9 m; all died 3-43 m 
following relapse (Figure 3). Of these 10 patients, four (40%) received CSI at first 
relapse, two (20%) received focal re-irradiation and four (40%) received no further 
radiotherapy. Five-year OS for the 22 patients treated with intention for 
HDC+AuSCR was 14% (3-36%) with median survival of 12 m; only three patients 
survived and the others all died 3-35 m following relapse (Figure 3). Of these 22 
patients, five (23%) received focal re-irradiation at first relapse, eight (36%) received 
CSI and nine (41%) received no further irradiation. Data analysis was performed on 
the basis of physician intention to treat, but 6/22 patients (27%) did not receive 
HDC+AuSCR because either they experienced further disease progression and died 
before initiation of HDC, or because they were too clinically unwell to receive it. Of 
the 16 patients who actually received HDC+AuSCR, 13 died (range 3-35 m), one is 
alive with SD (at 88 m follow-up) and two patients are in CR (at 105 m and 127 m). It 
is of note that the two CR patients both received additional radiation. 
 
Associations with survival in relapsed CNS GCTs. Clinico-pathological factors were 
interrogated for potential associations with clinical outcome. Firstly, patients who 
relapsed following an original diagnosis of germinoma (n=11) had better 5-year EFS 
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and OS than those who relapsed following an original diagnosis of NGGCT (n=32) 
(p=0.01 and p=0.007, respectively) (Figure 2). In the latter group, the only three 
survivors were all noted to have raised serum/CSF HCG levels alone (defined as HCG 
>50 IU/l at either diagnosis or relapse). Comparing the NGGCT relapse group treated 
with curative intent (n=32), regardless of relapse treatment received (intention for 
HDC+AuSCR or SDC), this ‘raised HCG alone’ group (n=7) had significantly better 
5-year OS (3/7; 43%) than all other relapsed NGGCT patients (0/25; 0%), (p=0.003) 
(Figure 4A). To avoid potential confounding by relapse treatment received, we next 
repeated this HCG analysis for only the 22 relapsed NGGCT patients with intention to 
treat with HDC+AuSCR. This also demonstrated a significantly better 5-year OS 
(p=0.002) for the four patients with raised HCG alone (3/4 survivors; 75%) compared 
with all other patients in the HDC+AuSCR cohort (0/18 survivors; 0%) (Figure 4B). 
Within the ‘raised HCG alone’ group, there were, however, no significant differences 
in the maximum levels of HCG between the patients who survived (n=3; levels 113, 
4,664, 5,999 IU/L) and those who died (n=4; levels 608, 3,201, 3,559, 60,600 IU/L) 
(p=0.49). For other associations with clinical factors, see Supplementary Results. 
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Discussion 
 
Intracranial germ cell tumors (GCTs) are a rare, heterogeneous cancer group and first-
line treatments are generally successful, so relapse is rare
2,3,7
. Previous reports 
describing outcomes of patients with relapsed intracranial GCTs are therefore limited 
by either small sample size
14,18–22
, selection bias and/or variable first-line treatments 
14,15,21,23
. For  
example, eight of 21 patients described in one study
14
 and six of 20 patients in 
another
15
 evaluating HDC+AuSCR for relapsed intracranial GCTs had not received 
first-line radiotherapy, which would now be considered standard-of-care for both 
intracranial germinoma and NGGCT patients
2,4,22,24
. Consequently, treatments for 
relapsed disease remain varied with no consensus on optimal management
2
. To 
address these limitations, we collected data from UK and German patients with 
relapsed intracranial GCTs, treated with standardized, first-line treatment as per the 
European SIOP-CNS-GCT-96 trial protocol. This has allowed us to describe the 
treatment received and subsequent outcome of the largest cohort of patients with 
relapsed intracranial GCTs to date. Appropriately, patients with non-uniform first-line 
treatment, those relapsing with teratoma only and those treated palliatively at relapse 
were excluded from further outcome analysis. The results will inform future 
approaches to the management of this disease, with the aim of maximizing survival. 
 
Given the excellent EFS for patients with intracranial germinoma
5,25,26
, relapses were 
a very rare occurrence indeed – indeed we only identified a total of 13 such cases 
across two large national groups (UK/Germany) contributing to the European SIOP-
CNS-GCT-96 study. Consequently, this germinoma cohort represents a relatively 
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small and heterogeneous group, in terms of type of relapse (marker-negative vs. 
marker-positive) and relapse treatments delivered (SDC vs. HDC+AuSCR; re-
irradiation vs. none). Full details are provided in Supplementary Discussion. 
Outcomes for patients who relapsed following germinoma diagnosis were broadly 
similar, whether treated with SDC or HDC+AuSCR. It should also be emphasised that 
whilst no patient in this group receiving HDC+AuSCR had additional radiotherapy, 
all such patients who received SDC had further radiotherapy (focal or CSI), except for 
a single patient with extracranial relapse (patient G13). Re-irradiation is therefore 
likely to make an important contribution to the similar outcomes observed between 
the two chemotherapy groups. These data therefore support either treatment option for 
these patients.  
 
As expected, due to the inferior outcomes for patients with intracranial NGGCTs 
compared with germinoma
12,26
, relapses amongst this cohort were more common, 
with 45 cases identified. Of the 32 cases with uniform first-line therapy and malignant 
relapse treated with curative intent, outcomes were very poor. There were no 
survivors in the patient group treated with SDC, and long-term OS was only 14% for 
the group with physician intention-to-treat with HDC+AuSCR. Indeed, over a quarter 
of this latter cohort did not actually receive HDC+AuSCR as they either progressed 
during re-induction chemotherapy or were too unwell to receive it. The outcomes 
described here are inferior to survival rates reported in previous studies: the 33% four-
year survival rate described in a cohort of 12 patients
14
 and 59% three-year survival in 
a cohort of eleven patients
15
 with relapsed NGGCTs who received HDC+AuSCR 
following variable first-line therapy. It should be noted that if only those patients who 
actually went on to receive HDC+AuSCR with a thiotepa-based regimen are 
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considered, survival was 30% (three of 10 patients; Table 2) – similar to that 
previously described
14
. However, the overall inferior outcomes described here are 
more likely to be representative of this patient cohort as a whole. This is due to our 
study ensuring that outcome analyses were only performed on patients receiving 
uniform first-line treatment, and inclusion of cases from the time-of-relapse on a 
curative intention-to-treat basis, and not just those who responded well enough to 
proceed to HDC+AuSCR. Accordingly, patients need to be counselled regarding 
these poor outcomes at the time of relapse. 
 
Of note, the only three survivors within the NGGCT relapse group had raised HCG 
alone, either at original diagnosis or at relapse. All other patients, i.e. those with 
raised AFP, combined raised AFP and HCG, or those who were marker-negative but 
had EC confirmed on biopsy, all died following relapse, regardless of salvage therapy 
delivered. Furthermore, at relapse, those patients with raised HCG alone had 
improved OS, both for the group as a whole, and when just those patients with 
intention-to-treat with HDC+AuSCR were considered, where three of four patients 
with raised HCG were long-term survivors. Survival did not appear to be related to 
the actual HCG level however, because one of the three surviving patients had a 
maximum HCG level of 113 IU/L and the other two had levels >4,500 IU/L. 
Although the first patient had a level again potentially consistent with HCG 
production from syncytiotrophoblast within a pure germinoma, the other two patients 
had levels that all national groups would consider to represent the presence of CHC 
within the tumor. These observations do highlight, however, the importance of 
attempting to agree an internationally agreed cut-off/threshold for tumor-markers, in 
order to better understand the correlation between marker levels, histology and 
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clinical outcome 
2,27
. Such agreement will facilitate trials to improve survival rates for 
patients with NGGCT whilst avoiding unnecessary treatment for those with 
germinoma. HDC+AuSCR is therefore a treatment option for patients diagnosed 
initially with NGGCT and experiencing a malignant relapse, if curative intent is the 
aim
13
. Additional surgery and/or radiotherapy should also be delivered where feasible 
– it should be noted that of the three survivors, the two who had CR both received re-
irradiation. For commentary on EC subtype relapses
28
, see Supplementary Discussion. 
 
Recent advances in our biological understanding
29–33
 are likely to assist clinical 
management decisions in the future, through improved risk stratification systems and 
the identification of molecular targets that will help determine the selection of 
appropriate novel therapeutic agents, particularly for the NGGCT patient population 
that have inferior outcomes. Recent use of exome sequencing to identify common 
genomic mutations is one such example
29,30
 . Collection of serum/plasma and CSF 
may also facilitate non-invasive diagnosis using microRNA expression levels
31,32
 and 
risk stratification through identification of tumor mutations via CSF tumor DNA 
(ctDNA) analysis
33
. Embedding such non-invasive biological studies in future clinical 
trials is a particularly attractive strategy for trial groups where NGGCT tissue 
specimens are a scarce resource due to reliance on typical radiology and tumor 
markers for diagnosis. 
 
The main limitation of this study, as in previous reports
14
, is its retrospective nature. 
However, as relapse is a rare outcome of this infrequent malignancy, a prospective 
randomised trial of relapsed CNS GCT patients is unlikely to be feasible. In future, it 
will be important to ensure that prospective data collection is embedded routinely 
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within treatment guidelines, to facilitate the identification of optimal re-induction 
strategies and further assess the role of HDC in this setting.  
 
In conclusion, we present the largest cohort of patients with relapsed intracranial 
GCTs reported to date. This study benefits from the uniform manner in which patients 
received first-line treatment, including radiotherapy as standard-of-care. Patients with 
an original diagnosis of intracranial germinoma experiencing relapse were 
salvageable with SDC and re-irradiation and HDC+AuSCR with and without re-
irradiation. Patients relapsing following an original diagnosis of intracranial NGGCT 
fared very poorly; only patients with raised HCG levels alone survived in this series, 
and only then with HDC+AuSCR. Thiotepa-based HDC+AuSCR, with additional 
surgery and radiotherapy where feasible, is a treatment option at first malignant 
relapse for such patients, albeit with counselling regarding poor outcomes.  
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Legends to Figures and Tables 
 
Figure 1. Summary flow-diagram listing the 58 patients described in the study and 
their basic clinical characteristics. 
 
Figure 2. Kaplan-Meier curves comparing five-year A) event-free survival and B) 
overall survival for patients treated with curative intent: intracranial malignant relapse 
of germinoma (solid line) versus non-germinomatous germ-cell-tumor (NGGCT; 
broken line). 
 
Figure 3. Kaplan-Meier curves comparing five-year overall survival for patients 
treated with curative intent at first malignant relapse of intracranial non-
germinomatous germ-cell-tumor (NGGCT): intention for high-dose chemotherapy 
(solid line) versus those receiving standard-dose chemotherapy (broken line). N/S = 
non-significant. 
 
Figure 4. Kaplan-Meier curves comparing five-year overall survival for patients 
treated with curative intent at first malignant relapse of intracranial non-
germinomatous germ-cell-tumor (NGGCT) with: elevated levels of HCG alone (solid 
line) versus all other patients in the cohort* (broken line). Graphs show data for A) all 
32 patients regardless of malignant relapse treatment schedule and B) the 22 patients 
treated with intention for high-dose chemotherapy only. *i.e., all those patients with 
elevated levels of AFP, combined elevations of AFP/HCG and/or with a tissue 
diagnosis of EC either in the serum or CSF, at diagnosis and/or relapse. 
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Table 1. Details of the intracranial germinoma patients at relapse, description of 
relapse treatments received and outcomes. 
 
Table 2. Details of the intracranial non-germinomatous germ-cell-tumor (NGGCT) 
patients at relapse, description of relapse treatments received and outcomes. 
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Figure 1. Summary flow-diagram listing the 58 patients described in the study and their basic clinical characteristics. 
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Figure 2. Kaplan-Meier curves comparing five-year A) event-free survival and B) overall survival for patients treated with 
curative intent: intracranial malignant relapse of germinoma (solid line) versus non-germinomatous germ cell tumor (NGGCT; 
broken line). 
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Figure 3. Kaplan-Meier curves comparing five-year overall survival for patients treated with curative intent at first malignant 
relapse of intracranial non-germinomatous germ cell tumor (NGGCT): intention for high-dose chemotherapy (solid line) versus 
those receiving standard-dose chemotherapy (broken line). N/S = non-significant. 
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log-rank test p = N/S
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A 
B 
Figure 4. Kaplan-Meier curves comparing five-year overall survival for patients treated with curative intent at first malignant 
relapse of intracranial non-germinomatous germ cell tumor (NGGCT) with: elevated levels of HCG alone (solid line) versus all 
other patients in the cohort (broken line). Graphs show data for A) all 32 patients regardless of malignant relapse treatment 
schedule and B) the 22 patients treated with intention for high-dose chemotherapy only.  
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Table 1. Details of the intracranial germinoma patients at relapse, description of relapse treatments received and outcomes. 
 
 
 
 
 
 
Patient 
number 
Site(s) of 
disease at 
relapse 
Elevated 
tumor 
markers 
identified 
at relapse? 
Diagnosis at 
relapse 
Surgery for 
relapse? 
HDC 
or 
SDC? 
Chemotherapy 
received 
Radioth
erapy 
received 
Response Morbidity 
described? 
Further 
relapses? 
Outcome Time (from 
relapse) of 
death or 
latest follow 
up (months) 
Included in 
further 
analysis? 
G1 Ventricular No Presumed 
germinoma 
No SDC Re-induction (carboPEI) Focal CR None None DOC (sepsis, 
brainstem 
impairment) 
16 Yes 
G4 Distant 
intracranial 
No Immature 
teratoma 
(histology)  
Total 
resection 
SDC Re-induction (carboPEI) No CR Metabolic 
imbalance 
3 (treatment 
included HDC) 
DOD 10 No (immature 
teratoma) 
G5 Primary No Germinoma 
(histology) 
Total 
resection 
HDC Re-induction (PEI); 
HDC (carbo/etop) 
No CR None None AND 194 Yes 
G7 Primary No Presumed 
germinoma 
No HDC Re-induction 
(carboPEI);  
HDC (thiotepa/etop) 
None CR Infection None DOC 
(pneumonitis) 
5 Yes 
G8 Ventricular No Presumed 
germinoma 
No SDC Re-induction (PEI) Focal CR None 1 (treatment 
included HDC) 
AND 92 Yes 
G9 Distant 
intracranial 
No Presumed 
germinoma 
No N/A None None N/A N/A None DOD 0 No (palliative) 
G10 Extracranial 
(skeletal) 
No Germinoma 
(histology) 
Biopsy HDC Re-induction (PEI); 
HDC (thiotepa/etop) 
None CR Panhypopituit
arism 
None AND 53 Yes 
G11 Distant 
intracranial 
No Germinoma 
(histology) 
Partial 
resection 
SDC Re-induction (other) Focal CR Panhypopituit
arism 
None AND 148 Yes 
G2 Leptomenin
geal 
HCG CHC 
(markers) 
No SDC Re-induction (other) CSI CR Electrolyte 
imbalance, 
seizures 
2 (treatment 
included HDC) 
DOD 47 Yes 
G3 Primary AFP YST 
(markers) 
No HDC Re-induction (PEI); 
HDC (not specified) 
No PD Febrile 
neutropenia 
None DOD 8 Yes 
G6 Primary AFP Germinoma 
(histology); 
YST 
(markers) 
Total 
resection 
SDC Re-induction (PEI) Focal PD None 1 (treatment not 
specified) 
DOD 8 Yes 
G12 Ventricular 
and 
leptomening
eal 
HCG CHC 
(markers) 
No SDC Re-induction (PEI) CSI CR DI None AND 62 Yes 
G13 Extracranial 
(abdominal 
via VPS) 
HCG Germinoma 
(cytology of 
ascites) but 
CHC 
(markers) 
Total 
resection of 
residual after 
chemotherapy 
SDC Re-induction (JEB) No CR None None AND 75 Yes 
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Abbreviations:  
SDC = standard-dose chemotherapy, HDC = high-dose chemotherapy 
CHC = choriocarcinoma 
YST = yolk sac tumor  
MGCT = malignant germ cell tumor  
 
CarboPEI = carboplatin, etoposide, ifosfamide  
PEI = cisplatin, etoposide, ifosfamide  
carbo/etop = carboplatin, etoposide 
thiotepa/etop = thiotepa, etoposide  
JEB = carboplatin, etoposide, bleomycin 
 
CSI = craniospinal irradiation  
 
CR = complete response, PR = partial response, PD = progressive disease  
 
AFP = alpha-fetoprotein; defined as elevated in serum or cerebrospinal fluid when levels >25 ng/ml 
HCG = human chorionic gonadotrophin, defined as elevated in serum or cerebrospinal fluid when levels >50 IU/l  
 
DOD = died of disease, DOC = died of complication, AND = alive with no disease  
 
N/A = not applicable  
DI = diabetes insipidus 
VPS = ventriculo-peritoneal shunt 
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Table 2: Details of the intracranial non-germinomatous germ-cell-tumor (NGGCT) patients at relapse, description of relapse treatments received and outcomes. 
 
Patient 
number 
Site(s) of 
disease at 
relapse 
Elevated AFP 
serum or CSF 
levels 
identified at 
relapse? 
Elevated 
HCG serum 
or CSF levels 
identified at 
relapse? 
Diagnosis 
and 
additional 
histological 
confirmation 
Surgery 
for 
relapse? 
Intention 
to treat 
with 
HDC + 
AuSCR 
Received 
HDC? 
Chemotherapy 
received 
Subsequent 
radiotherapy 
Response Morbidity Number of 
further 
relapses and 
treatment 
received 
Outcome Time of 
death 
from 1st 
relapse 
(months) 
Included 
in 
analysis? 
NG1 Distant 
intracranial 
+ - YST 
(markers) 
No Yes No Re-induction 
(carboPEI); HDC 
not received – 
disease progression 
Focal PD Neurological 
(seizures) 
N/A DOD 13 Yes 
NG2 Primary + - YST 
(markers) 
Subtotal 
resection 
Yes Yes Re-induction 
(carboPEI); HDC 
(thiotepa-based) 
Focal PR Toxicity from 
chemotherapy 
(not 
specified) 
None DOD 7 Yes 
NG3 Distant 
intracranial 
- ++ CHC 
(markers) 
No Yes Yes Re-induction 
(carboPEI); HDC 
(etop) 
None CR None 1 (HDC) DOD 18 Yes 
NG4 Not 
specified 
- - Teratoma 
(histology) 
Subtotal 
resection 
N/A N/A None None PR None 1 (surgery) DOD 30 No 
(teratoma) 
NG5 Primary, 
ventricular, 
spinal 
+ - Germinoma 
(histology), 
YST 
(markers) 
Subtotal 
resection 
Yes Yes Not specified None PD None None DOD 6 Yes 
NG6 Primary - - Teratoma 
(histology) 
Total 
resection 
N/A N/A None None CR None None AND 65 No 
(teratoma) 
NG7 Primary - - Presumed 
NGGCT 
No N/A N/A None None N/A N/A N/A DOD 2 No 
(palliative) 
NG8 Primary - - Presumed 
NGGCT 
No Yes No Re-induction (not 
specified); 
HDC not received – 
disease progression 
None PD Infection N/A DOD 3 Yes 
NG9 Primary + - YST 
(markers) 
No No N/A Re-induction 
(carbo/etop) 
Focal PD Infection None DOD 19 Yes 
NG10 Primary, 
distant 
intracranial, 
spinal 
+++ - YST 
(markers) 
Total 
resection 
Yes Yes Re-induction 
(carbo/etop); HDC 
(PEI) 
CSI PD None 1 (not 
specified) 
DOD 6 Yes 
NG11 Primary, 
spinal 
++ - YST 
(markers) 
No Yes Yes Re-induction 
(carbo/etop); HDC 
(thiotepa-based) 
CSI PR Infection 2 (SDC) DOD 35 Yes 
NG12 Distant 
intracranial 
- + CHC 
(markers) 
No No N/A Re-induction 
(carbo/etop) 
CSI CR Neurological 
(Guillain-
Barré 
syndrome) 
1 (palliative) DOD 12 Yes 
NG13 Primary, 
spinal 
- - Presumed 
NGGCT 
No Yes No Re-induction (PEI);  
HDC not received – 
disease progression 
None PD Not specified N/A DOD 3 Yes 
NG14 Primary + - YST 
(markers) 
No Yes Yes Re-induction 
(carbo/etop); HDC 
(etop) 
None CR Infection 1 (SDC) DOD 14 Yes 
NG15 Distant 
intracranial, 
spinal 
- ++ CHC 
(markers) 
No Yes Yes Re-induction 
(carboPEI); HDC 
(thiotepa-based) 
None SD None None ASD 88 Yes 
NG16 Primary, 
spinal 
- - Presumed 
NGGCT 
Metastas
es 
resected 
Yes Yes Re-induction and 
HDC (HD-PEI) 
CSI CR Not specified 1 (palliative) DOD 11 Yes 
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NG17 Primary + - YST 
(markers) 
No No N/A Ventricular 
etoposide 
CSI SD None 1 (palliative) DOD 8 Yes 
NG18 Primary, 
spinal 
- - Germinoma 
(histology) 
Subtotal 
resection 
No N/A Re-induction 
(carbo/etop) 
None PR Infection, 
respiratory 
and renal 
failure 
None DOD 10 Yes 
NG19 Distant 
intracranial 
Yes (levels not 
specified) 
- YST 
(markers) 
No No N/A Re-induction 
(carbo/etop) 
CSI PD Not specified 1 (SDC) DOD 9 No (non-
protocol 
first-line 
treatment) 
NG20 Primary - - Teratoma 
(histology) 
Total 
resection 
No N/A None None CR None None AND 79 No 
(teratoma) 
NG21 Distant 
intracranial 
- - Mixed 
MGCT 
(histology) 
Total 
resection 
No N/A None None PD None 5 (SDC) DOD 35 Yes 
NG22 Spinal - ++ CHC 
(markers), EC 
on initial 
biopsy 
No No N/A Re-induction (etop) None PD Not specified None DOD 3 Yes 
NG23 Spinal +++ - YST 
(markers) 
Biopsy Yes Yes Re-induction 
(carbo/cyclophos);  
HDC (thiotepa-
based) 
Focal PR None None DOD 11 Yes 
NG24 Primary, 
spinal 
+ - YST 
(markers) 
No N/A N/A Palliative (oral 
etoposide) 
Focal (to 
spine) 
PD Infection, 
seizures 
None DOD 7 No 
(palliative) 
NG25 Ventricular - - Presumed 
germinoma 
No N/A N/A None None N/A N/A None DOD 0 No 
(palliative) 
NG26 Distant 
intracranial 
++ - YST 
(markers) 
Total 
resection 
No N/A Re-induction (JEB) Focal CR Memory loss 1 (not 
specified) 
DOD 43 Yes 
NG27 Primary - ++ CHC 
(markers) 
No Yes Yes Re-induction 
(carbo/etop); HDC 
(thiotepa-based) 
None CR DI 1 (SDC) DOD 34 Yes 
NG28 Ventricular - +++ CHC 
(markers) 
No Yes Yes Re-induction 
(carbo/etop); HDC 
(thiotepa-based) 
Focal CR Extreme 
lethargy 
None AND 127 Yes 
NG29 Ventricular, 
spinal 
- + CHC 
(markers) 
No Yes Yes Re-induction 
(paclitaxel/etop/cispl
atin);  
HDC 
(etop/carbo/cycloph
os) 
None CR Hearing loss, 
mucositis 
1 (palliative) DOD 17 Yes 
NG30 Primary + - YST 
(markers) 
No Yes Yes Re-induction 
(carbo/etop); HDC 
(thiotepa-based) 
None PD Bone marrow 
suppression 
1 (HDC) DOD 11 Yes 
NG31 Primary, 
spinal 
+ - YST 
(markers), EC 
on initial 
biopsy 
No N/A N/A None CSI PD None None DOD 1 No 
(palliative) 
NG32 Spinal + - YST 
(markers) 
No Yes No Re-induction 
(cisplatin/etop/vinc);  
HDC not received – 
disease progression 
CSI PD None None DOD 12 Yes 
NG33 Distant 
intracranial 
++ - YST 
(markers), EC 
on initial 
biopsy 
No No N/A Re-induction 
(carbo/etop) 
None PD Toxicity from 
chemotherapy 
(not 
specified) 
None DOD 6 Yes 
NG34 Distant - - Presumed No Yes No Re-induction CSI PR Slow count None DOD 9 Yes 
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intracranial, 
spinal 
NGGCT, EC 
on initial 
biopsy 
(carbo/etop); HDC 
not received – 
toxicity of treatment 
recovery 
NG35 Ventricular - - Presumed 
germinoma 
(non-
diagnostic 
biopsy) 
Biopsy Yes Yes Re-induction 
(carbo/etop); HDC 
(thiotepa-based) 
CSI CR Mild LD, 
panhypopituit
arism 
None AND 105 Yes 
NG36 Primary +++ - YST 
(markers) 
No Yes Yes Re-induction 
(carbo/etop); HDC 
(carbo/etop) 
Not specified PD None None DOD 9 No (non-
protocol 
first-line 
treatment) 
NG37 Spinal - - CHC 
(cytology) 
No No N/A Re-induction 
(carbo/etop); then 
vinblastine/etop 
CSI PD Tumour 
caused cord 
compression 
None DOD 4 Yes 
NG38 Spinal ++ - YST 
(markers) 
No Yes Yes Re-induction 
(carbo/etop/cycloph
os); HDC (thiotepa-
based) 
CSI PD Minimal 1 (HDC) 
 
DOD 12 Yes 
NG39 Primary - - Teratoma 
(histology) 
Partial 
resection 
No N/A None None PR Seizures, 
hemiplegia, 
LD, 
panhypopituit
arism 
None ASD 120 No 
(teratoma) 
NG40 Primary + - YST 
(markers) 
No Yes Yes Re-induction 
(carbo/etop/cycloph
os); HDC (thiotepa-
based) 
Focal PR Intensive care 
after HDC 
1 (palliative) DOD 21 Yes 
NG41 Spinal ++ - YST 
(markers) 
Not 
specified 
No N/A Re-induction (not 
specified) 
Not specified Not 
specified 
Leucopenia None DOD 2 No (non-
protocol 
first-line 
treatment) 
NG42 Leptomenin
geal 
- + CHC 
(markers) 
No N/A N/A None – palliative 
treatment only 
None N/A N/A None DOD 1 No 
(palliative) 
NG43 Spinal + - YST 
(markers) 
Total 
resection 
Yes No Re-induction (JEB); 
HDC not received – 
clinically too unwell 
CSI CR Candida 
endocarditis, 
DI, shunt 
problems 
1 (not 
specified) 
DOD 0 Yes 
NG44 Primary, 
distant 
intracranial 
- - Teratoma 
(histology) 
Total 
resection 
N/A N/A None None PD None None DOD 3 No 
(teratoma) 
NG45 Leptomenin
geal 
- - Presumed 
NGGCT 
None No N/A None CSI PD None None DOD 4 Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations:  
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NGGCT = non-germinomatous germ cell tumor  
YST = yolk sac tumor  
CHC = choriocarcinoma  
 
SDC = standard-dose chemotherapy, HDC = high-dose chemotherapy 
 
CSF = cerebrospinal fluid 
AFP = alpha-fetoprotein; defined as elevated in serum or cerebrospinal fluid when levels >25 ng/ml 
HCG = human chorionic gonadotrophin, defined as elevated in serum or cerebrospinal fluid when levels >50 IU/l  
 
Marker key: 
 
AFP: 
-       refers to levels ≤25 ng/ml 
+      refers to levels >25 but <200 ng/ml 
++    refers to levels ≥200 but <1000 ng/ml 
+++  refers to levels ≥1000 ng/ml  
 
HCG:  
-       refers to levels ≤50 IU/l 
+      refers to levels >50 but <200 IU/l 
++    refers to levels ≥200 but <1000 IU/l 
+++  refers to levels ≥1000 IU/l 
 
 
PEI = cisplatin, etoposide, ifosfamide  
carboPEI = carboplatin, etoposide, ifosfamide  
PEI = cisplatin, etoposide, ifosfamide  
carbo/etop = carboplatin, etoposide 
carbo/etop/cyclophos = carboplatin, etoposide, cyclophosphamide  
thiotepa/etop = thiotepa, etoposide  
cisplatin/etop/vinc = cisplatin, etoposide, vincristine  
paclitaxel, etop/carbo/cyclophos = paclitaxel, etoposide, carboplatin, cyclophosphamide  
JEB = carboplatin, etoposide, bleomycin 
 
CSI = craniospinal irradiation  
RT = radiotherapy  
 
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease  
DOD = died of disease, DOC = died of complication, ASD = alive with stable disease, AND = alive with no disease 
 
LD = learning difficulties 
DI = diabetes insipidus 
 
N/A = not applicable  
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